Invasive breast cancer: Ki-67 evaluation in 3909 early breast cancer patients

Amato, Alessandra; Mercanti, Anna; Fiorio, Elena; Mandarà, Marta; Giovannini, M; Pavarana, M.; Caldara, A.; Micciolo, Rocco; Cetto, Gianluigi; Molino, A.

doi:10.1200/jco.2005.23.16_suppl.678

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neo-adjuvant chemotherapy (NAC) can reduce tumor burden, reduce tumor volume, reduce tumor stage, increase patient's chance of surgery, and increase breast-conserving rate by eliminating tumor cells. At the same time, we could also obtain information on the response of the tumor to the treatment through tumor size change and pathological change, it will be a great help for developing a treatment plan [5] [6] in next step, then avoid the blindness of postoperative chemotherapy, improve the quality of life for patients. Because of its advantage in lowering the stage for primary tumor, NAC has become a standard treatment for patients with late-stage breast cancer [7] [8] [9].…”

Section: Discussionmentioning

confidence: 99%

The Effect of Neoadjuvant Chemotherapy on ER, PR and HER-2 Expression in Breast Cancer

Zheng¹

2019

View full text Add to dashboard Cite

Objective: Through comparativing the change of the ER, PR and HER-2 expression in tumor tissue before and after neoadjuvant chemotherapy (NAC) in locally advanced breast cancer patient, to discuss whether there is influence for NACon ER, PR, HER-2 expression for breast cancer. Also, the relationship of ER, PR, HER-2 and chemosensitivity is also discussed. Methods: The expressions of ER, PR and HER2 in paraffin sections of breast cancer tissues from 51 patients before and after NAC were detected by immunohistochemical method. The assessment for the relationships between ER, PR, HER-2 and the efficiently of NAC is done. Results: For the 51 peoples, there is no statistical significance for change of ER, PR and HER-2 expression before and after NAC (P > 0.05). There is statistical significance for the differences of chemotherapeutic effectiverate between ER negative and ER positive, PR negative and PR positive, HER2 over-expressed group and HER2 non over-expressed group (P < 0.05). Pathological complete response (pCR) was related to molecular classification and the number of chemotherapy cycles. There is statistically significant or prognisis difference about hormone receptor, HER2 over-expressed and three-negative breast cancer (P < 0.05). Conclusion: NAC maybe could not change the expression of ER and PR, and HER2 for breast cancer patients. The patients with HER-2 over-expressed are not sensitive to chemotherapy, and the patients with ER or PR negative get more benefits from chemotherapy. The breast cancer patients who could obtain pCR could get better prognosis after NAC.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effect of Neoadjuvant Chemotherapy on ER, PR and HER-2 Expression in Breast Cancer

Zheng¹

2019

View full text Add to dashboard Cite

show abstract

Invasive breast cancer: Ki-67 evaluation in 3909 early breast cancer patients

Cited by 1 publication

References 0 publications

The Effect of Neoadjuvant Chemotherapy on ER, PR and HER-2 Expression in Breast Cancer

The Effect of Neoadjuvant Chemotherapy on ER, PR and HER-2 Expression in Breast Cancer

Contact Info

Product

Resources

About